Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
About this item
Full title
Author / Creator
Vannucchi, Alessandro M , Kiladjian, Jean Jacques , Griesshammer, Martin , Masszi, Tamas , Durrant, Simon , Passamonti, Francesco , Harrison, Claire N , Pane, Fabrizio , Zachee, Pierre , Mesa, Ruben , He, Shui , Jones, Mark M , Garrett, William , Li, Jingjin , Pirron, Ulrich , Habr, Dany and Verstovsek, Srdan
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was associated with hematocrit control and spleen size reduction in 21% of patients with polycythemia vera who had an inadequate response to or unacceptable side effects from hydroxyurea.
Polycythemia vera is a chronic clonal myeloproliferative neoplasm characterized by increased red-...
Alternative Titles
Full title
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4358820
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4358820
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1409002
